Amylyx Pharmaceuticals Inc (NAS:AMLX)
$ 2.23 0.01 (0.45%) Market Cap: 151.82 Mil Enterprise Value: -154.85 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 21/100

Amylyx Pharmaceuticals Inc To Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program Transcript

Jul 26, 2023 / 05:30PM GMT
Release Date Price: $22.83 (+1.47%)
Lindsey Allen

Good afternoon, and thank you all for joining us today to discuss the treatment landscape for people living with Progressive Supranuclear Palsy or PSP, and our clinical development plans for AMX0035 and PSP. With me on the call today are Josh Cohen and Justin Klee, our Co-CEOs. Dr. Jamie Timmons, Head of Global Medical Strategy and Communications. Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital in Munich, Germany and who will be our primary investigator on the Global Phase III clinical trial of AMX0035 and PSP. And Dr. Lahar Mehta, our Head of Global Clinical Development. Joining us for Q&A will be Jim Frates, our Chief Financial Officer. (Operator Instructions)

Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot